Two human papillomavirus (HPV) vaccines (Gardasil ® and Cevarix TM ) were launched between 2006~2007. Clinical trials have been performed in several countries. However, it takes few decades to measure HPV vaccine efficacy for the protection of cervical cancer. Therefore, several surrogate markers such as seroconversion rate, presence of HPV DNA, and cytological/ histological abnormalities have been evaluated. Until now, long-term follow-up data for 5 years (Gardasil) and for 8.4 years (Cevarix) were available from international trials. However, only seroconversion rate at 4 weeks after vaccination and safety were evaluated in Korea. It is necessary to establish a reference laboratory and long-term follow-up monitoring system for the proper evaluation of HPV vaccines in Korea. 
In the PATRICIA and FUTURE trials, case ascertainment for efficacy endpoints began after first vaccine dose in the TVC and ITT populations, and after the third vaccine dose in the ATP-E and per protocol populations (the day after the third dose in PATRICIA, and one month after the third dose in FUTURE). †
The studies were originally planned to last for 4 years, but the independent data and safety monitoring board recommend early termination so that women in the placebo group could receive the vaccine. 
